8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Jan 8, 2026·SEC
Phathom Pharmaceuticals, Inc.(PHAT)Earnings, Financials & Key Ratios
PHAT•NASDAQ
Price updated Jun 19, 2026
AboutPhathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Show more
- Revenue$175M+216.9%
- EBITDA-$159M+42.4%
- Net Income-$221M+33.8%
- EPS (Diluted)-3.03+42.7%
- Gross Margin87.09%+1.8%
- EBITDA Margin-91%+81.8%
- Operating Margin-91.36%+81.8%
- Net Margin-126.35%+79.1%
PHAT Key Insights
Phathom Pharmaceuticals, Inc. (PHAT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 11.4% over 5 years
- ✗Negative free cash flow
- ✗Shares diluted 15.4% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PHAT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PHAT Price & Volume
Phathom Pharmaceuticals, Inc. (PHAT) stock price & volume — 10-year historical chart
Loading chart...
PHAT Growth Metrics
Phathom Pharmaceuticals, Inc. (PHAT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM150.3%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM63.29%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM59.54%
Return on Capital
10 Years-76.74%
5 Years-80.39%
3 Years-74.83%
Last Year-76.24%
PHAT Recent Earnings
Phathom Pharmaceuticals, Inc. (PHAT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 5/12 qtrs (50%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$0.37-37.0%
$0.27
Rev
$58M+4.3%
$56M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.16+49.9%
$0.32
Rev
$58M+0.7%
$57M
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$0.15+50.0%
$0.30
Rev
$50M-13.8%
$57M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.79-3.9%
$0.76
Rev
$40M-15.5%
$47M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.37vs $0.27-37.0% | $58Mvs $56M+4.3% |
| Q1 2026 | Feb 26, 2026 | $0.16vs $0.32+49.9% | $58Mvs $57M+0.7% |
| Q4 2025 | Oct 30, 2025 | $0.15vs $0.30+50.0% | $50Mvs $57M-13.8% |
| Q3 2025 | Aug 7, 2025 | $0.79vs $0.76-3.9% | $40Mvs $47M-15.5% |
Based on last 12 quarters of dataView full earnings history →
PHAT Peer Comparison
Phathom Pharmaceuticals, Inc. (PHAT) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 SUPN | 2.56B | 44.38 | -65.26 | 8.63% | -3.74% | -2.73% | 0.04 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 IRWD | 582.73M | 3.54 | 23.60 | -15.72% | 28.26% | |||
 PTGX | 7.26B | 112.86 | -55.05 | -89.41% | -6.48% | -17.76% | 0.02 | |
 MDGL | 11.66B | 505.75 | -39.36 | 432.05% | -27.32% | -50.15% | 0.59 | |
 TAK | 48.84B | 15.63 | 39.28 | 4.28% | 4.25% | 2.62% | 0.63 | |
 AZN | 271.19B | 174.93 | 26.75 | 8.63% | 17.19% | 22.24% | 0.61 |
Compare PHAT vs Peers
Phathom Pharmaceuticals, Inc. (PHAT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PHAT Income Statement
Phathom Pharmaceuticals, Inc. (PHAT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 682K | 55.25M | 175.11M | 204.89M |
Revenue Growth % | - | - | - | - | - | - | 8001.47% | 216.93% | 150.3% |
Cost of Goods Sold | 0 | 8K | 300K | 521K | 620K | 167K | 7.97M | 22.6M | 30.87M |
COGS % of Revenue | - | - | - | - | - | 24.49% | 14.43% | 12.91% | - |
Gross Profit | 0▲ 0% | -8K▲ 0% | -300K▼ 3650.0% | -521K▼ 73.7% | -620K▼ 19.0% | 515K▲ 183.1% | 47.28M▲ 9080.4% | 152.51M▲ 222.6% | 174.02M▲ 0% |
Gross Margin % | - | - | - | - | - | 75.51% | 85.57% | 87.09% | 84.93% |
Gross Profit Growth % | - | - | -3650% | -73.67% | -19% | 183.06% | 9080.39% | 222.58% | - |
Operating Expenses | 1.23M | 106.22M | 125.36M | 134.56M | 171.82M | 167.83M | 324.75M | 312.5M | 270.62M |
OpEx % of Revenue | - | - | - | - | - | 24608.06% | 587.75% | 178.46% | - |
Selling, General & Admin | 1.21M | 6.94M | 27.22M | 62.22M | 100.38M | 117.93M | 290.66M | 279.72M | 239.25M |
SG&A % of Revenue | - | - | - | - | - | 17291.5% | 526.07% | 159.74% | - |
Research & Development | 20K | 99.27M | 98.15M | 72.34M | 71.44M | 49.9M | 34.08M | 32.78M | 31.37M |
R&D % of Revenue | - | - | - | - | - | 7316.57% | 61.68% | 18.72% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -1.23M▲ 0% | -106.22M▼ 8570.6% | -125.67M▼ 18.3% | -135.08M▼ 7.5% | -172.44M▼ 27.7% | -167.31M▲ 3.0% | -277.47M▼ 65.8% | -159.99M▲ 42.3% | -96.6M▲ 0% |
Operating Margin % | - | - | - | - | - | -24532.55% | -502.18% | -91.36% | -47.15% |
Operating Income Growth % | - | -8570.61% | -18.31% | -7.49% | -27.66% | 2.97% | -65.84% | 42.34% | - |
EBITDA | 0 | -106.21M | -125.36M | -134.56M | -171.82M | -166.74M | -276.67M | -159.35M | -96.14M |
EBITDA Margin % | - | - | - | - | - | -24448.24% | -500.75% | -91% | -46.92% |
EBITDA Growth % | - | - | -18.04% | -7.33% | -27.69% | 2.96% | -65.93% | 42.4% | 66.34% |
D&A (Non-Cash Add-back) | 1.23M | 8K | 300K | 521K | 620K | 575K | 795K | 633K | 456K |
EBIT | -1.27M | -250.95M | -124.49M | -137.09M | -170.42M | -159.62M | -262.32M | -159.99M | -81.12M |
Net Interest Income | 0 | -3.09M | -3.49M | -6.75M | -25.17M | -34.09M | -56.85M | -61.07M | -45.64M |
Interest Income | 0 | 1.09M | 1.09M | 41K | 2.13M | 7.88M | 15.16M | 7.04M | 6.14M |
Interest Expense | 13K | 4.18M | 4.58M | 6.79M | 27.3M | 41.97M | 72.01M | 68.11M | 34.25M |
Other Income/Expense | -63K | -148.92M | -3.4M | -8.8M | -25.28M | -34.28M | -56.86M | -61.26M | -45.81M |
Pretax Income | -1.29M▲ 0% | -255.13M▼ 19708.3% | -129.07M▲ 49.4% | -143.88M▼ 11.5% | -197.72M▼ 37.4% | -201.59M▼ 2.0% | -334.33M▼ 65.8% | -221.25M▲ 33.8% | -126.93M▲ 0% |
Pretax Margin % | - | - | - | - | - | -29558.94% | -605.09% | -126.35% | -61.95% |
Income Tax | 13K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -1.01% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -1.29M▲ 0% | -209.74M▼ 16184.5% | -129.07M▲ 38.5% | -143.88M▼ 11.5% | -197.72M▼ 37.4% | -201.59M▼ 2.0% | -334.33M▼ 65.8% | -221.25M▲ 33.8% | -126.93M▲ 0% |
Net Margin % | - | - | - | - | - | -29558.94% | -605.09% | -126.35% | -61.95% |
Net Income Growth % | - | -16184.47% | 38.46% | -11.48% | -37.42% | -1.96% | -65.84% | 33.82% | 63.29% |
Net Income (Continuing) | -1.29M | -255.13M | -129.07M | -143.88M | -197.72M | -201.59M | -334.33M | -221.25M | -126.93M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.15▲ 0% | -8.48▼ 5553.3% | -4.01▲ 52.7% | -4.00▲ 0.2% | -5.70▼ 42.5% | -3.93▲ 31.1% | -5.29▼ 34.6% | -3.03▲ 42.7% | -1.55▲ 0% |
EPS Growth % | - | -5553.33% | 52.71% | 0.25% | -42.5% | 31.05% | -34.61% | 42.72% | 59.54% |
EPS (Basic) | -0.15 | -8.48 | -4.01 | -4.00 | -5.70 | -3.93 | -5.29 | -3.03 | - |
Diluted Shares Outstanding | 8.58M | 24.73M | 33.23M | 37M | 39.12M | 51.29M | 63.18M | 72.92M | 82.05M |
Basic Shares Outstanding | 8.58M | 24.73M | 33.23M | 37M | 39.12M | 51.29M | 63.18M | 72.92M | 82.05M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
PHAT Balance Sheet
Phathom Pharmaceuticals, Inc. (PHAT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 902K | 255.6M | 291.37M | 186.53M | 160.51M | 397.43M | 360.13M | 228.97M | 276.57M |
Cash & Short-Term Investments | 879K | 243.76M | 287.5M | 183.26M | 155.38M | 381.39M | 297.26M | 129.97M | 180.9M |
Cash Only | 879K | 243.76M | 287.5M | 183.26M | 155.38M | 381.39M | 297.26M | 129.97M | 180.9M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 82K | 0 | 0 | 1.64M | 38.8M | 78.13M | 80.72M |
Days Sales Outstanding | - | - | - | - | - | 876.11 | 256.3 | 162.85 | 118.42 |
Inventory | 0 | 0 | -82K | 0 | 0 | 1.21M | 3.21M | 5.52M | 6.51M |
Days Inventory Outstanding | - | - | - | - | - | 2.64K | 146.86 | 89.12 | 56.36 |
Other Current Assets | 0 | 0 | 3.87M | 3.27M | 5.13M | 13.19M | 20.87M | 15.35M | 8.44M |
Total Non-Current Assets | 0 | 1.58M | 3.74M | 2.9M | 4.3M | 16.41M | 18.18M | 30.18M | 28.55M |
Property, Plant & Equipment | 0 | 1.4M | 3.36M | 2.56M | 3.49M | 3.62M | 2.09M | 3.67M | 3.52M |
Fixed Asset Turnover | - | - | - | - | - | 0.19x | 26.45x | 47.75x | 62.30x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 505K | 0 | 2.86M | 0 | 5.72M |
Other Non-Current Assets | 0 | 181K | 384K | 341K | 299K | 12.79M | 13.23M | 26.51M | 25.02M |
Total Assets | 902K▲ 0% | 257.18M▲ 28412.0% | 295.11M▲ 14.7% | 189.43M▼ 35.8% | 164.81M▼ 13.0% | 413.84M▲ 151.1% | 378.32M▼ 8.6% | 259.15M▼ 31.5% | 305.12M▲ 0% |
Asset Turnover | - | - | - | - | - | 0.00x | 0.15x | 0.68x | 0.78x |
Asset Growth % | - | 28411.97% | 14.75% | -35.81% | -13% | 151.1% | -8.58% | -31.5% | -87.39% |
Total Current Liabilities | 2.19M | 3.75M | 55.52M | 18.92M | 26.24M | 38.78M | 85.73M | 132.04M | 125.04M |
Accounts Payable | 55K | 699K | 16.78M | 5.15M | 10M | 12.6M | 10.51M | 4.98M | 6.37M |
Days Payables Outstanding | - | 31.89K | 20.42K | 3.61K | 5.89K | 27.54K | 481.01 | 80.48 | 48.57 |
Short-Term Debt | 1.95M | 0 | 7.35M | 0 | 0 | 0 | 19.78M | 648K | 667K |
Deferred Revenue (Current) | -1.95M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 413K | 0 | 0 | 0 | 20.43M | 54.94M | 126.41M | 118.01M |
Current Ratio | 0.41x | 68.20x | 5.25x | 9.86x | 6.12x | 10.25x | 4.20x | 1.73x | 2.21x |
Quick Ratio | 0.41x | 68.20x | 5.25x | 9.86x | 6.12x | 10.22x | 4.16x | 1.69x | 2.16x |
Cash Conversion Cycle | - | - | - | - | - | -24.02K | -77.85 | 171.49 | 126.21 |
Total Non-Current Liabilities | 0 | 25.48M | 45.32M | 98.35M | 213.39M | 447.82M | 546.17M | 565.27M | 517.03M |
Long-Term Debt | 0 | 22.78M | 39.63M | 89.67M | 95.26M | 137.84M | 534.67M | 2.06M | 1.96M |
Capital Lease Obligations | 0 | 635K | 1.56M | 1.18M | 1.1M | 462K | 0 | 0 | 589K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 2.06M | 4.13M | 7.5M | 117.03M | 309.52M | 11.5M | 563.21M | 515.07M |
Total Liabilities | 2.19M | 29.22M | 100.84M | 117.28M | 239.62M | 486.6M | 631.9M | 697.32M | 642.08M |
Total Debt | 1.95M | 23.57M | 49.02M | 91.34M | 97.07M | 139.03M | 554.95M | 2.71M | 2.63M |
Net Debt | 1.07M | -220.19M | -238.48M | -91.92M | -58.31M | -242.36M | 257.68M | -127.26M | -178.28M |
Debt / Equity | - | 0.10x | 0.25x | 1.27x | - | - | - | - | -0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.03x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 1.85x |
Interest Coverage | -98.08x | -60.08x | -27.17x | -20.20x | -6.24x | -3.80x | -3.64x | -2.35x | -2.37x |
Total Equity | -1.29M▲ 0% | 227.96M▲ 17825.9% | 194.27M▼ 14.8% | 72.16M▼ 62.9% | -74.81M▼ 203.7% | -72.76M▲ 2.7% | -253.58M▼ 248.5% | -438.17M▼ 72.8% | -336.95M▲ 0% |
Equity Growth % | - | 17825.89% | -14.78% | -62.86% | -203.68% | 2.75% | -248.52% | -72.79% | -271.75% |
Book Value per Share | -0.15 | 9.22 | 5.85 | 1.95 | -1.91 | -1.42 | -4.01 | -6.01 | -4.11 |
Total Shareholders' Equity | -1.29M | 227.96M | 194.27M | 72.16M | -74.81M | -72.76M | -253.58M | -438.17M | -336.95M |
Common Stock | 0 | 2K | 3K | 3K | 3K | 5K | 6K | 6K | 7K |
Retained Earnings | -1.29M | -256.42M | -385.49M | -529.37M | -727.09M | -928.68M | -1.26B | -1.48B | -1.51B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PHAT Cash Flow Statement
Phathom Pharmaceuticals, Inc. (PHAT) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -1.02M | -36.51M | -69.69M | -148.46M | -146.53M | -137.58M | -266.77M | -166.78M | -97.49M |
Operating CF Margin % | - | - | - | - | - | -20173.02% | -482.82% | -95.24% | - |
Operating CF Growth % | - | -3468.91% | -90.87% | -113.03% | 1.3% | 6.11% | -93.9% | 37.48% | 262.79% |
Net Income | -1.29M | -255.13M | -129.07M | -143.88M | -197.72M | -201.59M | -334.33M | -221.25M | -126.93M |
Depreciation & Amortization | 0 | 8K | 323K | 521K | 620K | 575K | 795K | 633K | 566K |
Stock-Based Compensation | 0 | 406K | 5.84M | 16.81M | 24.13M | 45.02M | 24.05M | 28.72M | 28.71M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 50K | 227.73M | 1.5M | 5.41M | 21M | 32.06M | 58.01M | 37.5M | 33.99M |
Working Capital Changes | 215K | -9.52M | 51.72M | -27.32M | 5.44M | -13.64M | -15.3M | -12.38M | -3.46M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | -1.64M | -37.16M | -39.33M | -44.36M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | -9.44M | -6.14M | -11.78M | 1.21M |
Change in Payables | 225K | 2.27M | 24.01M | -9.79M | 8.68M | 6.41M | 34.94M | 34.1M | 37.94M |
Cash from Investing | 0 | -25.25M | -1.04M | -328K | -1.04M | -1.63M | -135K | -229K | -272K |
Capital Expenditures | 0 | -132K | -1.04M | -328K | -1.04M | -1.63M | -135K | -229K | 18K |
CapEx % of Revenue | - | - | - | - | - | 239.59% | 0.24% | 0.13% | 0.01% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -25.12M | 0 | 0 | 0 | 0 | 0 | 0 | -290K |
Cash from Financing | 1.9M | 304.65M | 114.46M | 44.71M | 120.04M | 367.58M | 182.77M | -288K | 66.35M |
Debt Issued (Net) | 1.9M | 113.17M | 25M | 42.76M | 95.45M | 39.32M | 59.4M | 0 | 0 |
Equity Issued (Net) | 0 | 191.47M | 88.83M | 0 | 24.6M | 155.46M | 121.78M | 1.64M | 0 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 2K | 0 | 629K | 1.94M | 0 | 172.8M | 1.6M | -1.93M | 66.35M |
Net Change in Cash | 879K▲ 0% | 242.89M▲ 27532.1% | 43.73M▼ 82.0% | -104.08M▼ 338.0% | -27.87M▲ 73.2% | 228.37M▲ 919.3% | -84.13M▼ 136.8% | -167.29M▼ 98.8% | -31.41M▲ 0% |
Free Cash Flow | -1.02M▲ 0% | -61.76M▼ 5937.1% | -70.73M▼ 14.5% | -148.78M▼ 110.4% | -147.57M▲ 0.8% | -139.21M▲ 5.7% | -266.9M▼ 91.7% | -166.78M▲ 37.5% | -97.4M▲ 0% |
FCF Margin % | - | - | - | - | - | -20412.61% | -483.07% | -95.24% | -47.54% |
FCF Growth % | - | -5937.15% | -14.52% | -110.36% | 0.82% | 5.66% | -91.72% | 37.52% | 65.54% |
FCF per Share | -0.12 | -2.50 | -2.13 | -4.02 | -3.77 | -2.71 | -4.22 | -2.29 | -1.19 |
FCF Conversion (FCF/Net Income) | 0.79x | 0.17x | 0.54x | 1.03x | 0.74x | 0.68x | 0.80x | 0.75x | 0.77x |
Interest Paid | 0 | 1.01M | 3.46M | 4.07M | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PHAT Key Ratios
Phathom Pharmaceuticals, Inc. (PHAT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -185.07% | -61.14% | -108.01% | - | - | - | - | 31.66% |
Return on Invested Capital (ROIC) | -2110.79% | - | - | - | - | - | - | 17.93% |
Gross Margin | - | - | - | - | 75.51% | 85.57% | 87.09% | 84.93% |
Net Margin | - | - | - | - | -29558.94% | -605.09% | -126.35% | -61.95% |
Debt / Equity | 0.10x | 0.25x | 1.27x | - | - | - | - | -0.01x |
Interest Coverage | -60.08x | -27.17x | -20.20x | -6.24x | -3.80x | -3.64x | -2.35x | -2.37x |
FCF Conversion | 0.17x | 0.54x | 1.03x | 0.74x | 0.68x | 0.80x | 0.75x | 0.77x |
Revenue Growth | - | - | - | - | - | 8001.47% | 216.93% | 150.3% |
Related:PHAT Dividend History·PHAT Revenue History·PHAT Price History·PHAT P/E History·PHAT Financial Ratios·PHAT Institutional Holders
PHAT SEC Filings & Documents
Phathom Pharmaceuticals, Inc. (PHAT) SEC filings — annual & quarterly reports (10-K, 10-Q)
PHAT Frequently Asked Questions
Phathom Pharmaceuticals, Inc. (PHAT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Phathom Pharmaceuticals, Inc. (PHAT) reported $204.9M in revenue for fiscal year 2025.
Phathom Pharmaceuticals, Inc. (PHAT) grew revenue by 216.9% over the past year. This is strong growth.
Phathom Pharmaceuticals, Inc. (PHAT) reported a net loss of $126.9M for fiscal year 2025.
Dividend & Returns
Phathom Pharmaceuticals, Inc. (PHAT) had negative free cash flow of $97.4M in fiscal year 2025, likely due to heavy capital investments.